The FDA announced a pilot effort to review clinical trial data in real time, aiming to reduce reporting lag and improve reviewer access as data accrues. The agency said the program will build on two proof-of-concept efforts underway with Amgen and AstraZeneca. The FDA also asked for public input on a broader pilot concept that could incorporate AI for safety monitoring, dose selection support, signal detection, and recruitment improvements. The initial studies highlighted include an AstraZeneca Phase 2 lymphoma trial at MD Anderson and the University of Pennsylvania, and an Amgen Phase 1b small-cell lung cancer trial. The move targets speed in the information loop between sponsors and regulators, potentially shortening the timeline to regulatory discussions while keeping the focus on safety and signal evaluation.